EBM Technologies Incorporated (TPEX:8409)
17.75
-0.35 (-1.93%)
Nov 12, 2026, 1:30 PM CST
EBM Technologies Revenue
EBM Technologies had revenue of 67.44M TWD in the quarter ending September 30, 2026, a decrease of -40.66%. This brings the company's total for the last twelve months to 237.52M, down -31.83% year-over-year. In the year 2025, EBM Technologies had annual revenue of 253.11M, down -9.91%. That makes EBM Technologies the 38,705th largest company in the world by revenue and 2,016th in Taiwan.
Revenue (ttm)
237.52M
Revenue Growth
-31.83%
P/S Ratio
2.45
Revenue / Employee
n/a
Employees
n/a
Market Cap
568.00M
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full EBM Technologies breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 253.11M | -27.85M | -9.91% |
| Dec 31, 2024 | 280.95M | 74.81M | 36.29% |
| Dec 31, 2023 | 206.15M | -177.74M | -46.30% |
| Dec 31, 2022 | 383.88M | 188.95M | 96.93% |
| Dec 31, 2021 | 194.93M | -20.40M | -9.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 24.62B |
| Perfect Medical Industry | 886.30M |
| Taiwan Advance Bio-Pharmaceutical | 348.54M |
| General Biologicals | 260.23M |
| Lukas Biomedical | 170.01M |
| Neith | 31.84M |
| SynCore Biotechnology Co.,Ltd | 26.24M |
| Caliway Biopharmaceuticals | 15.98M |